BioMarin Pharmaceutical Price Target Raised to $88.00 at William Blair (BMRN)
Investment analysts at William Blair increased their price target on shares of BioMarin Pharmaceutical (NYSE:BMRN) from $74.00 to $88.00 in a note issued to investors on Wednesday, Stock Ratings Network reports. William Blair’s price objective would indicate a potential upside of 13.56% from the company’s current price.
BMRN has been the subject of a number of other recent research reports. Analysts at Stifel Nicolaus downgraded shares of BioMarin Pharmaceutical (NYSE:BMRN) from a “buy” rating to a “hold” rating in a research note to investors on Wednesday. Separately, analysts at RBC Capital raised their price target on shares of BioMarin Pharmaceutical (NYSE:BMRN) from $66.00 to $77.00 in a research note to investors on Wednesday. They now have an “outperform” rating on the stock. Finally, analysts at Jefferies Group raised their price target on shares of BioMarin Pharmaceutical (NYSE:BMRN) from $72.00 to $86.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock.
One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. BioMarin Pharmaceutical currently has an average rating of “Buy” and an average price target of $84.20.
BioMarin Pharmaceutical (NYSE:BMRN) traded up 2.02% during mid-day trading on Wednesday, hitting $77.492. 3,191,145 shares of the company’s stock traded hands. BioMarin Pharmaceutical has a 1-year low of $36.28 and a 1-year high of $78.83. The stock has a 50-day moving average of $67.2 and a 200-day moving average of $63.36. The company’s market cap is $10.857 billion.
BioMarin Pharmaceutical Inc (NYSE:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.